This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, J. Articles by Ferrans, V. J. Search for Related Content PubMed PubMed Citation Articles by Zhang, J. Articles by Ferrans, V. J.

Circulation, Vol 87, 1340-1353, Copyright © 1993 by American Heart Association

ARTICLES

Cardiotoxicity of human recombinant interleukin-2 in rats. A morphological study

J Zhang, ZX Yu, SL Hilbert, M Yamaguchi, DP Chadwick, EH Herman and VJ Ferrans
Division of Research and Testing, Food and Drug Administration, Washington, D.C.

BACKGROUND. One of the side effects of interleukin 2 (IL-2) cancer immunotherapy in humans is the vascular leak syndrome, which is frequently associated with depression of myocardial function, myocarditis, and myocardial necrosis. METHODS AND RESULTS. To investigate this cardiotoxicity, IL-2 (three doses of 5 x 10(5) Cetus units/day i.p.) was given to rats for 2, 3, or 5 days. Heart, lung, liver, spleen, and kidney tissues were studied by light and electron microscopy and with immunoperoxidase techniques. Cardiac changes consisted of focal lymphocytic and eosinophilic infiltration, myocyte vacuolization, myofibrillar loss, and necrosis. Ultrastructural alterations included swelling of endothelial cells, with dissociation of intercellular junctions, migration of lymphocytes into the interstitium, and interstitial hemorrhage and edema. Close contact between infiltrating lymphocytes, particularly large granular lymphocytes, and cardiac myocytes was often observed in areas of tissue damage. All lesions were more severe on day 5 than on days 2 and 3. Immunoperoxidase stains demonstrated asialo GM1 ganglioside antibody- positive, granular lymphocytes to be much more frequent in myocardium of IL-2-treated rats than in that of control rats. CONCLUSIONS. Although we cannot exclude the possibility of a direct toxic effect of IL-2 on myocytes, our observations suggest that the myocardial damage produced by this agent is triggered by IL-2-activated lymphocytes that exert cytolytic effects, first on endothelial cells and then on cardiac myocytes, thus producing lesions that involve both the cardiac microcirculation and the muscle cells.

This article has been cited by other articles:

				A. Nicoletti and J.-B. Michel Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors Cardiovasc Res, March 1, 1999; 41(3): 532 - 543. [Abstract] [Full Text] [PDF]

				G. Grassl, C. L. Pummerer, I. Horak, and N. Neu Induction of Autoimmune Myocarditis in Interleukin-2–Deficient Mice Circulation, April 1, 1997; 95(7): 1773 - 1776. [Abstract] [Full Text]

				Jun Zhang, R. J. Wenthold JR., Z.-X. Yu, E. H. Herman, and V. J. Ferrans Characterization of the Pulmonary Lesions Induced in Rats by Human Recombinant Interleukin-2 Toxicol Pathol, November 1, 1995; 23(6): 653 - 666. [Abstract] [PDF]

				H. Takada, C. Kishimoto, and Y. Hiraoka Therapy With Immunoglobulin Suppresses Myocarditis in a Murine Coxsackievirus B3 Model : Antiviral and Anti-inflammatory Effects Circulation, September 15, 1995; 92(6): 1604 - 1611. [Abstract] [Full Text]

				S. Fujita, R. Puri, Z.-X. Yu, W. Travis, M. Yamaguchi, and V. J. Ferrans Interleukin-la Reduces the Severity of the Vascular Leak Syndrome Produced by Interleukin-2 and Interleukin-2 Plus Interferon-a Toxicol Pathol, July 1, 1994; 22(4): 381 - 397. [Abstract] [PDF]